
    
      The study was conducted as an open label, balanced, randomised, two-treatment, two-period,
      two-sequence, single-dose, crossover , bioavailability study on clarithromycin formulations
      comparing clarithromycin 500mg tablets of Ranbaxy Laboratories with BiaxinÂ® tablets 500mg
      (containing clarithromycin 500 mg)in healthy, adult, human, male subjects under fasting
      conditions

      Eligible subjects underwent pre-study examinations that included a physical examination,
      12-lead ECG, and laboratory tests - including hematology, blood chemistries, urinalysis,
      infectious diseases (Hepatitis B, Hepatitis Ci HIV), and urine drugs of abuse. Laboratory
      testing for female subjects also included a serum pregnancy test.
    
  